BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...
Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON, September 22, 2025--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback